Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week

Reuters

Nov 06

<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week

Maze Therapeutics Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria (PKU) and chronic kidney disease (CKD). Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD). The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570150-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581622270"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581622270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581622270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581622270","market":"fut","top_or_hot":-1,"title":"Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a> Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maze <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria (PKU) and chronic kidney disease (CKD). Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD). The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570150-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAZE\">Maze Therapeutics</a> Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maze <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria (PKU) and chronic kidney disease (CKD). Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD). The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570150-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5kl21N:1","article_id":"2581622270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581622270","pubTimestamp":1762430480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maze Therapeutics Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria  and chronic kidney disease . Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease . The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4007":"制药","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","MAZE":"Maze Therapeutics","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股"},"translate_title":"Maze Therapeutics在ASN肾脏周上强调了肾脏疾病药物有希望的1期和2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MAZE":0.9},"content_text":"Maze Therapeutics Highlights Promising Phase 1 and 2 Data for Kidney Disease Drugs at ASN Kidney Week\n    \n\n        Maze Therapeutics Inc. announced it will present updated data from its two lead programs, MZE782 and MZE829, at the American Society of Nephrology's Kidney Week, held November 6-9, 2025, in Houston, Texas. The company will share additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, a novel oral SLC6A19 inhibitor being developed as a potential therapy for both phenylketonuria (PKU) and chronic kidney disease (CKD). Preclinical research supporting the inhibition of SLC6A19 to slow CKD progression will also be presented. Additionally, Maze Therapeutics will discuss research on MZE829, an oral small molecule inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD). The presentations will include both new clinical and preclinical findings and are scheduled throughout the conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570150-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}